SCHEMBL2836740

SCHEMBL2836740

CNCc1cn(Cc2ccc(F)cc2)c(-c2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
SLC6A4 P31645 1/20 0.42
CNR2 P34972 4/20 0.41
CNR1 P21554 3/20 0.41
FAAH O00519 1/20 0.41
ABHD12 Q8N2K0 1/20 0.41
SERPINE1 P05121 1/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2835333 0.99 CYP11B1 (0.45) CYP11B1CYP11B2HTR2AHTR2CSLC6A4
SCHEMBL29114936 0.77 BRD4 (0.53) CYP11B1CYP11B2SERPINE1KMT2AALDH1A1
SCHEMBL10332224 0.76 GABRA1 (0.46) CYP11B1CYP11B2ALDH1A1KDM4EGAA
SCHEMBL2834778 0.73 ALDH1A1 (0.45) CYP11B1CYP11B2KMT2AALDH1A1MAPT
Oxalic Acid SCHEMBL2838926 0.72 ALDH1A1 (0.44) CNR2CNR1FAAHKMT2AALDH1A1
Hydrochloric Acid SCHEMBL2834768 0.70 MAPT (0.42) KMT2AALDH1A1MAPTKDM4EGAA
SCHEMBL9786782 0.70 BRD4 (0.63) CYP11B1CYP11B2ALDH1A1KDM4ENPSR1
Hydrochloric Acid SCHEMBL2835467 0.68 ALDH1A1 (0.43) KMT2AALDH1A1MAPTKDM4EMEN1
SCHEMBL29114962 0.67 BRD4 (0.57) CYP11B1CYP11B2KMT2AALDH1A1MAPT
Hydrochloric Acid SCHEMBL2838733 0.67 CD274 (0.38) ALDH1A1MAPTKDM4ELMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP claimed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US claimed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP claimed
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP disclosed
US-8334301-B2 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-18 US disclosed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND NPY4R, NPY5R, NPY1R CYP11B1 26/4885CYP11B2 31/4885HTR2A 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.